Echocardiographic evaluation of left ventricular filling pressures in patients with pulmonary hypertension

Hong Ran1, Matthias Schneider2, Anna Maria Pistritto3

  • 1Department of Echocardiography, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.

Insights

The 2016 echocardiography guidelines more accurately estimate left ventricular filling pressures in pulmonary hypertension patients than the 2009 guidelines. This improved accuracy aids in diagnosing diastolic dysfunction in this population.

Area of Science:

  • Cardiology
  • Echocardiography
  • Pulmonary Hypertension

Background:

  • Echocardiographic assessment of diastolic dysfunction relies on surrogate parameters.
  • Current guidelines use diagnostic flowcharts to classify left ventricular filling pressures (LVFP).
  • The accuracy of these tools can be limited by non-diastolic causes of elevated surrogate parameters, such as in pulmonary hypertension (PH).

Purpose of the Study:

  • To compare the diagnostic accuracy of the 2009 and 2016 echocardiographic guideline recommendations for assessing diastolic function.
  • To evaluate the effectiveness of these guidelines in estimating left ventricular filling pressures (LVFP) specifically in patients with pulmonary hypertension (PH).

Main Methods:

  • Retrospective analysis of 101 consecutive patients undergoing right heart catheterization and echocardiography for suspected PH.
  • Inclusion of 63 PH patients in the final analysis.
  • Application of both 2009 and 2016 echocardiographic guideline recommendations for diastolic function assessment.

Main Results:

  • The 2016 recommendations showed higher sensitivity (84%) and similar specificity (80%) compared to the 2009 recommendations (67% sensitivity, 82% specificity).
  • The area under the receiver operating characteristic curve (AUC) for the 2016 guidelines (0.82) was significantly better than for the 2009 guidelines (0.74) (p=0.04).
  • 43% of the included PH patients had elevated LVFP.

Conclusions:

  • The 2016 echocardiographic guidelines demonstrate superior accuracy in estimating LVFP in patients with PH compared to the 2009 guidelines.
  • Updated guidelines improve the diagnostic capability for diastolic dysfunction in the context of pulmonary hypertension.
  • These findings support the adoption of the 2016 recommendations for improved clinical decision-making in PH patients.

Related Concept Videos

Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
642
Hypertension and Regulation of Blood Pressure01:18

Hypertension and Regulation of Blood Pressure

Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
4.2K
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
600
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
464
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
507
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
616